Burney Company’s Protagonist Therapeutics PTGX Stock Holding History

Burney Company’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$390K	Hold	3,179	–	–	0.01%	492
2026 Q1	$335K	Sell	3,179 -501	-14%	-$44.4K	0.01%	485
2025 Q4	$321K	Sell	3,680 -1,384	-27%	-$113K	0.01%	514
2025 Q3	$336K	Sell	5,064 -1,254	-20%	-$71.3K	0.01%	484
2025 Q2	$349K	Sell	6,318 -195,667	-97%	-$9.39M	0.01%	472
2025 Q1	$9.77M	Buy	+201,985	New	+$8.46M	0.36%	75

Other funds holding PTGX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Cache Advisors San Francisco, California $1.18B AUM 44.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Burney Company's PTGX Position: Q2 2026 in Review

Burney Company held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 3,179 shares worth $390K. The position accounts for 0.01% of the portfolio, ranked #492.

Burney Company first reported a position in PTGX in Q1 2025 and has held it in 6 quarters since. The position peaked at $9.77M in Q1 2025. 31 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Burney Company held 3,179 shares of Protagonist Therapeutics worth $390K as of Q2 2026.
Burney Company left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 0.01% of Burney Company's portfolio in Q2 2026, its #492 holding.
Burney Company first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 6 quarters since.
Burney Company's Protagonist Therapeutics position peaked at $9.77M in Q1 2025.
31 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Burney Company's 13F filing for Q2 2026, filed 15 Jul 2026.